{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:40:25Z","timestamp":1790883625505,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["PDA141311"],"award-info":[{"award-number":["PDA141311"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 18855"],"award-info":[{"award-number":["IG 18855"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Microbiology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.tim.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T18:19:59Z","timestamp":1526062799000},"page":"865-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":241,"title":["Drug Repurposing for Viral Infectious Diseases: How Far Are We?"],"prefix":"10.1016","volume":"26","author":[{"given":"Beatrice","family":"Mercorelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Pal\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Loregian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tim.2018.04.004_bib0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrd.2016.244","article-title":"Applications of chemogenomic library screening in drug discovery","volume":"16","author":"Jones","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tim.2018.04.004_bib0010","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.3595","article-title":"Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks","volume":"20","author":"Strittmatter","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.tim.2018.04.004_bib0015","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2018.04.004_bib0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijantimicag.2016.07.004","article-title":"Fighting viruses with antibiotics: an overlooked path","volume":"48","author":"Colson","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.tim.2018.04.004_bib0025","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2014.12.054","article-title":"Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein","volume":"10","author":"Strating","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.tim.2018.04.004_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.tim.2013.03.006","article-title":"How academic labs can approach the drug discovery process as a way to synergize with big pharma","volume":"21","author":"Loregian","year":"2013","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.tim.2018.04.004_bib0035","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1473-3099(16)30010-X","article-title":"Zika virus: history of a newly emerging arbovirus","volume":"16","author":"Wikan","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2018.04.004_bib0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of Zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tim.2018.04.004_bib0045","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"Xu","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.tim.2018.04.004_bib0050","doi-asserted-by":"crossref","first-page":"14408","DOI":"10.1073\/pnas.1618029113","article-title":"Zika virus cell tropism in the developing human brain and inhibition by azithromycin","volume":"113","author":"Retallack","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2018.04.004_bib0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.antiviral.2017.07.007","article-title":"Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection invitro and invivo","volume":"145","author":"Yuan","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0060","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/cr.2017.88","article-title":"Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction","volume":"27","author":"Li","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0065","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.celrep.2016.12.068","article-title":"Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against Zika virus","volume":"18","author":"Rausch","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.tim.2018.04.004_bib0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.stem.2017.06.017","article-title":"High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit Zika virus infection in fetal-like organoids and adult brain","volume":"21","author":"Zhou","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tim.2018.04.004_bib0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2016.11.018","article-title":"Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay","volume":"138","author":"Adcock","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.08.007","article-title":"Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice","volume":"146","author":"Kamiyama","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2017.09.004","article-title":"Cell-line dependent antiviral activity of sofosbuvir against Zika virus","volume":"146","author":"Mumtaz","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0095","article-title":"Blocking Zika virus vertical transmission","volume":"8","author":"Mesci","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tim.2018.04.004_bib0100","article-title":"The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication","volume":"7","author":"Sacramento","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tim.2018.04.004_bib0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.antiviral.2016.11.015","article-title":"Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus","volume":"137","author":"Balasubramanian","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0110","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/v8120322","article-title":"Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models","volume":"8","author":"Delvecchio","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.tim.2018.04.004_bib0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15467-6","article-title":"Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis","volume":"7","author":"Shiryaev","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tim.2018.04.004_bib0120","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00350-17","article-title":"N-Methyl-d-aspartate (NMDA) receptor blockade prevents neuronal death induced by Zika virus infection","volume":"8","author":"Costa","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.tim.2018.04.004_bib0125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01055-17","article-title":"Screening of FDA-approved drugs for inhibitors of Japanese encephalitis virus infection","volume":"91","author":"Wang","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2018.04.004_bib0130","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1073\/pnas.0912966107","article-title":"Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection","volume":"107","author":"Gastaminza","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2018.04.004_bib0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bcp.2017.01.005","article-title":"Pharmacological intervention for dengue virus infection","volume":"129","author":"Lai","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tim.2018.04.004_bib0140","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/infdis\/jiu377","article-title":"Repurposing of prochlorperazine for use against dengue virus infection","volume":"211","author":"Simanjuntak","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2018.04.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010286","article-title":"Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection","volume":"7","author":"He","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tim.2018.04.004_bib0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.curtheres.2017.01.007","article-title":"Repurposed therapeutic agents targeting the Ebola virus: a systematic review","volume":"84","author":"Sweiti","year":"2017","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.tim.2018.04.004_bib0155","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.molmed.2017.07.002","article-title":"Clinical evaluation of Ebola virus disease therapeutics","volume":"23","author":"Liu","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tim.2018.04.004_bib0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40506-017-0130-z","article-title":"Discovering drugs for the treatment of Ebola virus","volume":"9","author":"Bixler","year":"2017","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"10.1016\/j.tim.2018.04.004_bib0165","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.tim.2018.04.004_bib0170","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.tim.2018.04.004_bib0175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tim.2018.04.004_bib0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tim.2018.04.004_bib0185","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.tim.2018.04.004_bib0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060579","article-title":"A systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tim.2018.04.004_bib0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tim.2018.04.004_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.11.003","article-title":"Teicoplanin inhibits Ebola pseudovirus infection in cell culture","volume":"125","author":"Wang","year":"2016","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0205","first-page":"280","article-title":"Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process","volume":"71","author":"Salata","year":"2015","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.tim.2018.04.004_bib0210","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430 \u2013 A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.tim.2018.04.004_bib0215","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bph.13895","article-title":"Drug repurposing screens and synergistic drug-combinations for infectious diseases","volume":"175","author":"Zheng","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tim.2018.04.004_bib0220","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0225","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.tim.2018.04.004_bib0230","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2018.04.004_bib0235","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2018.04.004_bib0240","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.tim.2018.04.004_bib0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.virusres.2016.11.011","article-title":"Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model","volume":"228","author":"de Wilde","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0250","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2018.04.004_bib0255","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13063-017-2427-0","article-title":"Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-\u03b21b (MIRACLE trial): study protocol for a randomized controlled trial","volume":"19","author":"Arabi","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.tim.2018.04.004_bib0260","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","article-title":"Antiviral strategies against influenza virus: towards new therapeutic approaches","volume":"71","author":"Loregian","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tim.2018.04.004_bib0265","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3389\/fmicb.2017.02130","article-title":"Pharmacodynamics, pharmacokinetics, and antiviral activity of BAY 81-8781, a novel NF-kappaB inhibiting anti-influenza drug","volume":"8","author":"Droebner","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.tim.2018.04.004_bib0270","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2017.07.016","article-title":"Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses","volume":"145","author":"Hu","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0275","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2018.04.004_bib0280","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.chest.2016.11.012","article-title":"Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb\/III trial","volume":"151","author":"Hung","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.tim.2018.04.004_bib0285","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/anie.201511361","article-title":"Drug repurposing identifies inhibitors of oseltamivir-resistant influenza viruses","volume":"55","author":"Bao","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.tim.2018.04.004_bib0290","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0295","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2018.04.004_bib0300","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.antiviral.2017.11.013","article-title":"Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference","volume":"149","author":"McKimm-Breschkin","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0305","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.pharmthera.2011.04.007","article-title":"Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives","volume":"131","author":"Mercorelli","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tim.2018.04.004_bib0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2015.12.012","article-title":"Drug repurposing approach identifies inhibitors of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication","volume":"23","author":"Mercorelli","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.tim.2018.04.004_bib0315","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2014.10.011","article-title":"Development of a high-content screen for the identification of inhibitors directed against the early steps of the cytomegalovirus infectious cycle","volume":"113","author":"Gardner","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0320","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/jmv.23998","article-title":"Statins demonstrate a broad anti-cytomegalovirus activity in vitro in ganciclovir-susceptible and resistant strains","volume":"87","author":"Ponroy","year":"2015","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.tim.2018.04.004_bib0325","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1128\/AAC.00898-12","article-title":"Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene","volume":"56","author":"Kapoor","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2018.04.004_bib0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005717","article-title":"Efficacy and mechanism of action of low dose emetine against human cytomegalovirus","volume":"12","author":"Mukhopadhyay","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2018.04.004_bib0335","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1074\/mcp.M116.065375","article-title":"Kinome profiling identifies druggable targets for novel human cytomegalovirus (HCMV) antivirals","volume":"16","author":"Arend","year":"2017","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.tim.2018.04.004_bib0340","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.antiviral.2017.12.014","article-title":"Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein","volume":"150","author":"Mercorelli","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2018.04.004_bib0345","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/jvh.12479","article-title":"Identification of FDA-approved drugs that target hepatitis B virus transcription","volume":"23","author":"van de Klundert","year":"2016","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.tim.2018.04.004_bib0350","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01318-14","article-title":"HIV integrase inhibitors block replication of alpha-, beta-, and gammaherpesviruses","volume":"5","author":"Yan","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.tim.2018.04.004_bib0355","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1073\/pnas.1007144107","article-title":"Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain","volume":"107","author":"Nadal","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2018.04.004_bib0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147917","article-title":"A single-arm, proof-of-concept trial of lopimune (lopinavir\/ritonavir) as a treatment for HPV-related pre-invasive cervical disease","volume":"11","author":"Hampson","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.tim.2018.04.004_bib0365","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/pr.117.013755","article-title":"Small-molecule screens: a gateway to cancer therapeutic agents with case studies of Food and Drug Administration-approved drugs","volume":"69","author":"Coussens","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tim.2018.04.004_bib0370","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tim.2018.04.004_bib0375","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001862","article-title":"The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics","volume":"3","author":"Huang","year":"2011","journal-title":"Sci. Transl. Med."}],"container-title":["Trends in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X18300878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X18300878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:39:07Z","timestamp":1760812747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966842X18300878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0966842X18300878"],"URL":"https:\/\/doi.org\/10.1016\/j.tim.2018.04.004","relation":{},"ISSN":["0966-842X"],"issn-type":[{"value":"0966-842X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Repurposing for Viral Infectious Diseases: How Far Are We?","name":"articletitle","label":"Article Title"},{"value":"Trends in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tim.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}